EMD Serono Presents New MAVENCLAD® (Cladribine) Tablets Data Highlighting Sustained Reduction in NfLs and Benefit of Early Initiation
ROCKLAND, Mass., October 10, 2023--EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of new analyses from the MAVENCLAD® (cladribine) tablets MAGNIFY-MS study, which demonstrated that patients with relapsing multiple sclerosis (RMS) experienced sustained reduction in serum neurofilament light chain (NfL), indicating that MAVENCLAD reduced neuronal injury over two years. Additional data include two real-worl...
Source: yahoo.com